β2-Adrenergic receptor gene polymorphisms in the relapse of myasthenia gravis with thymus abnormality
暂无分享,去创建一个
[1] Y. Nakazawa,et al. Reduction in peripheral regulatory T cell population in childhood ocular type myasthenia gravis , 2015, Brain and Development.
[2] Kazuhiro Suzuki,et al. Control of lymphocyte egress from lymph nodes through β2-adrenergic receptors , 2014, The Journal of experimental medicine.
[3] M. Foti,et al. Both Treg cells and Tconv cells are defective in the Myasthenia gravis thymus: roles of IL-17 and TNF-α. , 2014, Journal of autoimmunity.
[4] N. Eissa,et al. Deficiency of Autophagy in Dendritic Cells Protects against Experimental Autoimmune Encephalomyelitis* , 2014, The Journal of Biological Chemistry.
[5] J. Sieb. Myasthenia gravis: an update for the clinician , 2014, Clinical and experimental immunology.
[6] Shigeaki Suzuki,et al. Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis , 2013, Journal of Neuroimmunology.
[7] L. Klein,et al. Thymic epithelial cells use macroautophagy to turn their inside out for CD4 T cell tolerance , 2013, Autophagy.
[8] L. Yujun,et al. Association of single nucleotide polymorphisms of β2-adrenergic receptor gene with clinicopathological features of pancreatic carcinoma. , 2013, Acta histochemica.
[9] A. Keller,et al. Beta2‐adrenergic receptor signaling in CD4+ Foxp3+ regulatory T cells enhances their suppressive function in a PKA‐dependent manner , 2013, European journal of immunology.
[10] Z. Wang,et al. T Helper Type 17 Cells Expand in Patients with Myasthenia‐Associated Thymoma , 2012, Scandinavian journal of immunology.
[11] T. O. Olde Hartman,et al. Course and prognosis of myasthenia gravis: a systematic review , 2010, European journal of neurology.
[12] Xian-hao Xu,et al. Role of β2-adrenergic receptor polymorphisms in pathogenesis of myasthenia gravis , 2009 .
[13] G. Muscolino,et al. Thymoma-associated myasthenia gravis: Outcome, clinical and pathological correlations in 197 patients on a 20-year experience , 2008, Journal of Neuroimmunology.
[14] Ru-xun Huang,et al. [Prognostic factors related to recurrence after extended thymectomy in patients with myasthenia gravis]. , 2008, Zhonghua yi xue za zhi.
[15] R. Kukreti,et al. Pharmacogenomics of β2-agonist: key focus on signaling pathways , 2006 .
[16] W. Hsu,et al. Thymoma is associated with relapse of symptoms after transsternal thymectomy for myasthenia gravis. , 2005, Interactive cardiovascular and thoracic surgery.
[17] A. Zwinderman,et al. Genetic Inflammatory Factors Predict Restenosis After Percutaneous Coronary Interventions , 2005, Circulation.
[18] P. Rizzon,et al. Association of β-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy , 2004 .
[19] B. Xu,et al. ß2-Adrenergic receptor gene single-nucleotide polymorphisms are associated with rheumatoid arthritis in northern Sweden , 2004, Scandinavian journal of rheumatology.
[20] T. Kurihara,et al. Relapse of ocular symptoms after remission of myasthenia gravis—a comparison of relapsed and complete remission cases , 2003, Clinical Neurology and Neurosurgery.
[21] S. Kikuchi,et al. An examination of the association between b2 adrenergic receptor polymorphisms and multiple sclerosis , 2002, Multiple sclerosis.
[22] A. Bezjak,et al. Prognostic significance of thymomas in patients with myasthenia gravis. , 2002, The Annals of thoracic surgery.
[23] V. Sanders,et al. Norepinephrine and beta 2-adrenergic receptor stimulation regulate CD4+ T and B lymphocyte function in vitro and in vivo. , 2001, Pharmacological reviews.
[24] R. Barohn,et al. Myasthenia gravis , 2000, Neurology.
[25] R. Pirskanen,et al. β2‐adrenergic receptor gene polymorphisms in myasthenia gravis (MG) , 2000, Clinical and experimental immunology.
[26] R. Dixon,et al. Delineation of the intronless nature of the genes for the human and hamster beta 2-adrenergic receptor and their putative promoter regions. , 1987, The Journal of biological chemistry.